Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology
Portfolio Pulse from Benzinga Newsdesk
Nutriband Inc. has received a Notice of Allowance from the USPTO for its patent application covering Aversa™ abuse deterrent technology. The USPTO is expected to issue a U.S. patent after administrative processes are completed.
June 23, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nutriband Inc. receives Notice of Allowance for its Aversa™ abuse deterrent technology patent application, potentially strengthening its product portfolio.
The Notice of Allowance for Nutriband's Aversa™ abuse deterrent technology patent application indicates that the USPTO is likely to issue a patent after completing administrative processes. This development could strengthen Nutriband's product portfolio and potentially increase its market share in the transdermal pharmaceutical products sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Nutriband Inc.'s receipt of a Notice of Allowance for its Aversa™ abuse deterrent technology patent application may positively impact its stock.
The Notice of Allowance for Nutriband's Aversa™ abuse deterrent technology patent application indicates that the USPTO is likely to issue a patent after completing administrative processes. This development could strengthen Nutriband's product portfolio and potentially increase its market share in the transdermal pharmaceutical products sector, positively impacting its stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100